Pliant Therapeutics Inc is a biotechnology company focused on the development of innovative therapies for fibrotic diseases
The company is dedicated to discovering and advancing novel treatments that address the underlying mechanisms of tissue scarring and fibrosis across various organs. By leveraging its expertise in cellular and molecular biology, Pliant aims to transform the lives of patients suffering from debilitating conditions caused by excessive connective tissue growth, ultimately contributing to improved health outcomes and better quality of life.
Pliant Therapeutics ends its Phase 2b IPF trial for bexotegrast, prompting a Needham downgrade to Hold due to limited catalysts and pipeline challenges.
Pliant Therapeutics discontinued its BEACON-IPF trial for bexotegrast due to safety concerns but observed early efficacy. The company plans further data analysis.
Curious to know what's happening on the US markets one hour before the close of the markets on Monday? Join us as we explore the top gainers and losers in today's session.
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Monday. Let's explore the market movements and identify the stocks with significant gaps.
Pliant Therapeutics halted new enrollment in its BEACON-IPF trial after a safety board review. A separate study showed bexotegrast reduced lung collagen.
